OBJECTIVES: The co-transmitter neuropeptide Y (NPY) is released during high levels of sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of plasma NPY during acute ST elevation myocardial infarction, and tested the hypothesis that levels correlate with reperfusion measures after treatment with primary percutaneous coronary intervention (PPCI). DESIGN: Prospective observational study. SETTING: University hospital heart centre. PATIENTS: 64 patients (62.6±11.7 years-old, 73% male) presenting throughout the 24-h cycle of clinical activity with ST elevation myocardial infarction. INTERVENTIONS: PPCI. MAIN OUTCOME MEASURES: NPY was measured (ELISA) in peripheral blood taken before and immediately after PPCI and at 6, 24 and 48 h post-PPCI. Reperfusion was assessed by angiographic criteria, ST segment resolution, invasive measurement of coronary flow reserve and the index of microcirculatory resistance. RESULTS: Plasma NPY levels were highest before PPCI (17.4 (8.8-42.2) pg/ml, median (IQR)) and dropped significantly post-PPCI (12.4 (6.5-26.7) pg/ml, p<0.0001) and after 6 h (9.0 (2.6-21.5) pg/ml, p=0.008). Patients with admission NPY levels above the median were significantly more hypertensive and tachycardic and were more likely to have diabetes mellitus. Patients with angiographic no-reflow (less than thrombolysis in myocardial infarction 3 flow and myocardial blush grade >2, n=16) or no electrocardiographic ST resolution (<70%, n=30) following PPCI had significantly higher plasma NPY levels. Patients with a coronary flow reserve <1.5 or index of microcirculatory resistance >33 also had significantly higher plasma NPY levels pre-PPCI and post-PPCI. CONCLUSIONS: Plasma NPY levels correlate with indices of reperfusion and coronary microvascular resistance.
OBJECTIVES: The co-transmitter neuropeptide Y (NPY) is released during high levels of sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of plasma NPY during acute ST elevation myocardial infarction, and tested the hypothesis that levels correlate with reperfusion measures after treatment with primary percutaneous coronary intervention (PPCI). DESIGN: Prospective observational study. SETTING: University hospital heart centre. PATIENTS: 64 patients (62.6±11.7 years-old, 73% male) presenting throughout the 24-h cycle of clinical activity with ST elevation myocardial infarction. INTERVENTIONS:PPCI. MAIN OUTCOME MEASURES: NPY was measured (ELISA) in peripheral blood taken before and immediately after PPCI and at 6, 24 and 48 h post-PPCI. Reperfusion was assessed by angiographic criteria, ST segment resolution, invasive measurement of coronary flow reserve and the index of microcirculatory resistance. RESULTS: Plasma NPY levels were highest before PPCI (17.4 (8.8-42.2) pg/ml, median (IQR)) and dropped significantly post-PPCI (12.4 (6.5-26.7) pg/ml, p<0.0001) and after 6 h (9.0 (2.6-21.5) pg/ml, p=0.008). Patients with admission NPY levels above the median were significantly more hypertensive and tachycardic and were more likely to have diabetes mellitus. Patients with angiographic no-reflow (less than thrombolysis in myocardial infarction 3 flow and myocardial blush grade >2, n=16) or no electrocardiographic ST resolution (<70%, n=30) following PPCI had significantly higher plasma NPY levels. Patients with a coronary flow reserve <1.5 or index of microcirculatory resistance >33 also had significantly higher plasma NPY levels pre-PPCI and post-PPCI. CONCLUSIONS: Plasma NPY levels correlate with indices of reperfusion and coronary microvascular resistance.
Authors: B Wocial; H Ignatowska-Switalska; P Pruszczyk; P Jedrusik; A Januszewicz; M Lapinski; W Januszewicz; Z Zukowska-Grojec Journal: Blood Press Date: 1995-05 Impact factor: 2.835
Authors: L Gullestad; T Bjurø; L Aaberge; T Apelland; R Skårdal; E Kjekshus; M Nordlander; B Ablad; J Pernow Journal: Eur Heart J Date: 2003-06 Impact factor: 29.983
Authors: Neil Herring; James Cranley; Michael N Lokale; Dan Li; Julia Shanks; Eric N Alston; Beatrice M Girard; Emma Carter; Rodney L Parsons; Beth A Habecker; David J Paterson Journal: J Mol Cell Cardiol Date: 2011-12-07 Impact factor: 5.000
Authors: Alexander R Payne; Colin Berry; Orla Doolin; Margaret McEntegart; Mark C Petrie; M Mitchell Lindsay; Stuart Hood; David Carrick; Niko Tzemos; Peter Weale; Christie McComb; John Foster; Ian Ford; Keith G Oldroyd Journal: J Am Heart Assoc Date: 2012-08-24 Impact factor: 5.501
Authors: Olujimi A Ajijola; Daigo Yagishita; Naveen K Reddy; Kentaro Yamakawa; Marmar Vaseghi; Anthony M Downs; Donald B Hoover; Jeffrey L Ardell; Kalyanam Shivkumar Journal: Heart Rhythm Date: 2015-01-30 Impact factor: 6.343
Authors: Beth A Habecker; Mark E Anderson; Susan J Birren; Keiichi Fukuda; Neil Herring; Donald B Hoover; Hideaki Kanazawa; David J Paterson; Crystal M Ripplinger Journal: J Physiol Date: 2016-06-17 Impact factor: 5.182